Druggability & Clinical Context
Druggability
Low
Score: 0.40
Druggability Analysis
Structural Tractability0.70
Key Metrics
PDB Structures:
1
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
2 Preclinical
Therapeutic Areas:Alzheimer's disease Ischemic stroke Neuroinflammation Blood-brain barrier dysfunction Neurovascular disorders Traumatic brain injury Multiple sclerosis
Druggability Rationale: MLCK is moderately druggable (0.60 score) as a kinase target with well-characterized structural data (1.8 Å resolution, PDB: 6C6M) and existing research tools (ML-7, ML-9) demonstrating proof-of-concept inhibition. However, medium druggability reflects challenges in achieving selectivity across the kinase superfamily and potential off-target effects that may complicate clinical translation beyond phase 2.
Mechanism: MLCK inhibitors block the phosphorylation of myosin light chains, thereby reducing cytoskeletal contraction and stabilizing tight junctions at the blood-brain barrier and endothelial surfaces. This mechanism reduces vascular permeability and preserves barrier integrity in conditions characterized by excessive leakage or cytoskeletal dysfunction.
Drug Pipeline (2 compounds)
2 Preclinical
Known Drugs:ML-7 (research_tool) — myosin light chain kinase inhibition
ML-9 (research_tool) — myosin light chain kinase inhibition
Structural Data:PDB (1) ✓AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:MLCK contains a canonical ATP-binding pocket typical of serine/threonine kinases, with structural information available from PDB 6C6M at high resolution (1.8 Å). The ATP-binding site represents the primary druggable pocket; optimization of competitive inhibitors targeting this region while maintaining selectivity over related kinases remains a key medicinal chemistry focus.
Selectivity & Safety Considerations
MLCK selectivity is complicated by structural homology with other kinases; isoform selectivity between MLCK and MLCK-like kinases (e.g., MLCK-L) must be carefully characterized to avoid off-target cardiovascular or smooth muscle effects. Tight junction-specific targeting could be achieved through BBB permeability optimization rather than kinase selectivity alone.
Clinical Trials (4)
Relevant trials from ClinicalTrials.gov
NA
NCT01456767
n=10
Gastro Intestinal Infection
Interventions: Probiotics
Sponsor: Maastricht University Medical Center | Started: 2011-10
NA
NCT01877044
n=46
Obesity, Overweight
Interventions: NAXUS, Placebo
Sponsor: Maastricht University Medical Center | Started: 2013-01
NA
NCT05157867
n=8
Non-Coeliac Wheat Sensitivity (NCWS), Irritable Bowel Syndrome
Interventions: Amylase trypsin inhibitors, Placebo
Sponsor: Maastricht University | Started: 2023-09
NA
NCT05453188
n=30
COVID-19, Genetic Predisposition to Disease
Interventions: Experimental, Control
Sponsor: Universidad Francisco de Vitoria | Started: 2022-03-01